JPRN-jRCT2080223369未知1 期
A Phase 1 Study of the Safety and Tolerability of BMS-986012 in Subjects With Small Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Histological or cytological confirmed small cell lung cancer (SCLC)
- •Eastern Cooperative Oncology Group Performance Status 0-1
- •at least one measurable lesion that is not amenable to resection.
- •Adequate organ function
排除标准
- •Symptomatic central nervous system (CNS) metastases
- •Greater than or equal to Grade 2 peripheral neuropathy
- •Uncontrolled or significant cardiac disease
- •Active or chronic infection with Human Immunodeficiency Virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)
研究者
相似试验
未知
1 期
Phase 1 Study of BMS-986148Solid tumorsJPRN-jRCT2080223357Bristol-Myers Squibb K.K.15
招募中
1 期
utetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic non-small cell lung cancerMetastatic Non-small Cell Lung CancerCancer - Lung - Non small cellACTRN12623000959673Radiopharm Theranostics Ltd23
已完成
不适用
A phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumorsAdvanced solid tumoursSolid tumoursCancerISRCTN96787846OXiGENE, Inc. (USA)12
撤回
1 期
Safety and tolerability of the Traditional Chinese Medicine Formulation GOPAC in patients with advanced malignancyAdvanced malignancy (palliative)Cancer - Other cancer typesACTRN12609000652279Sydney South West Area Health Service70
未知
1 期
A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects (I8B-JE-ITRK)HealthyJPRN-jRCT2080223225Eli Lilly Japan K.K.